High performance drug development team
Our industry-leading team combines polymer and polysaccharide chemistry know-how with microbiology, infectious disease, and molecular biology expertise to design and manufacture advanced therapeutics. By targeting polysaccharide therapeutics to mucosal surface biology, we work to create breakthrough drugs for superior therapeutic impact.
William Wiesmann, MD
Dr. Wiesmann is an accomplished physician, medical scientist, and program manager with experience in cell biology, systems biology, medical device development and extensive experience leading and conducting basic scientific and medical research. He served as the Director for Combat Casualty Care at the U.S. Army Medical Research and Materiel Command Post, at Ft. Detrick, where he led the design and development teams that produced novel technologies for improved battlefield survival until he retired from the Army as a colonel in 1997. His innovations, which include the LSTAT Transportable Life Support System, the Advanced Surgical Suite for Trauma Casualties (ASSTC), the SAVe ventilators, and the HemCon hemostatic bandages, have transformed medicine both on the battlefield and in civilian trauma centers. In 2004, the military named the 4-by-4-inch HemCon bandage one of the year’s “Top 10 Greatest Inventions” for its ability to stop seriously wounded soldiers from bleeding to death. He holds 59 awarded or pending patents from his work in biosensors, automated diagnostic devices, advanced tissue engineering, wound care, and infection control. Dr. Wiesmann has been published in more than 75 peer-reviewed medical journals.
Dr. Wiesmann has received many honors for his development work in government, including the US Army Meritorious Service Medal, the US Army R & D Achievement Award, and the Army Commendation Medal. He was awarded an honorary Doctor of Science degree from the University of Cincinnati.
He is a co-founder of Hawaii Chitopure, BioSTAR West, Tissue Genesis, AutoMedx Inc., and Synedgen, Inc.
Shenda Baker, PhD
Dr. Shenda Baker is an experienced entrepreneur and scientist with expertise in polymer physics, macromolecular and surface chemistry and nanostructured materials. Dr Baker served as CEO for Synspira, bringing the first Synedgen licensed technology into clinical trials for inhaled treatment for patients with cystic fibrosis. Dr. Baker was a professor of Chemistry at Harvey Mudd College from 1991-2014 with a research focus on polymer nanostructures and self-assembly at liquid and solid interfaces. She has held strategic positions on the Board of Directors of the Materials Research Society and has served on advisory boards with the National Institutes of Health at the National Institutie for Dental and Cranofacial Research, National Science Foundation at the directorates of Math and Physical Sciences, Computer and Information Science and Engineering, the Advisory Committee for Cyber Infrastructure and at the Department of Energy. Dr. Baker is a member of the American Chemical Society and the Materials Research Society and currently serves on the Advisory Council of the National Institute of Dental and Craniofacial Research of the NIH. She is co-inventor on all of the Synedgen technology.
Christopher Ryan, PhD
Dr. Ryan leads operations at Synedgen and provides quality oversight for all products, including the Prisyna Oral Care portfolio, Wound Care portfolio, clinical trial material, and development material. He leads regulatory communication and documentation, provides scientific support throughout Synedgen’s product areas, and provides technical oversight for quality control, manufacturing, and contract manufacturing. Dr. Ryan has a background in host-pathogen interaction, molecular biology, and biochemistry, focusing on polysaccharide and RNA chemistry. At Synedgen, he has led cosmetics, OTC drugs, and medical devices from development through regulatory clearance to commercial production.
Kaveri Parker, PhD
Dr. Parker leads the commercialization and business development of all Synedgen product divisions, including Wound Care and Prisyna Oral Care, and assists in the expansion of strategic partnership opportunities across the spectrum of Synedgen’s product portfolio. Dr. Parker has an extensive background in biochemistry and infectious diseases, as well as years of business development and management experience. Most recently, she served as President and Chief Executive Officer of ID Genomics Inc. in Seattle, WA, where she led all aspects of executive management, including strategic and tactical planning, fundraising, path-to-market strategy, investor and media relations, as well as R&D capability scale-up. During her tenure, she secured strategic partnerships with 12 major clinical hospital networks across the U.S. and leveraged ID Genomics’ technology into an international microbial surveillance network.
Allister Loughran, PhD
Dr. Loughran is an innovative researcher in the fields of microbiology and immunology with a focus on host-pathogen interactions. As Senior Scientist, he provides scientific leadership, oversight and assay development for the screening of new molecules created as part of the glycomics technology platform. He leverages his broad scientific experiences to apply Synedgen’s glycomics technology platform to the discovery of treatments for new disease states. Dr. Loughran earned his BSc. in Microbiology and Molecular Biology at Monash University, Australia and PhD in Microbiology/Immunology at the University of Arkansas for Medical Sciences before completing a postdoctoral fellowship at St. Jude Children’s Research hospital.
With over ten years of financial management experience, Ms. York manages all daily finance operations, forecasting, and planning at Synedgen. Her varied expertise includes audits, job costing, process development and internal controls implementation in Manufacturing and Medical Device distribution industries. Ms. York holds a Bachelor of Arts in Business Management with an emphasis in Accounting.